Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer

BACKGROUND: FOLFOXIRI plus bevacizumab is used as a first-line therapy for patients with unresectable or metastatic colorectal cancer. However, there are no clear recommendations for second-line therapy after FOLFOXIRI plus bevacizumab combination. Here, we describe our planning for the EFFORT study...

Descripción completa

Detalles Bibliográficos
Autores principales: Satake, Hironaga, Ando, Koji, Oki, Eiji, Shimokawa, Mototsugu, Makiyama, Akitaka, Saeki, Hiroshi, Tsuji, Akihito, Mori, Masaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672899/
https://www.ncbi.nlm.nih.gov/pubmed/33203393
http://dx.doi.org/10.1186/s12885-020-07576-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672899/
https://www.ncbi.nlm.nih.gov/pubmed/33203393
http://dx.doi.org/10.1186/s12885-020-07576-9

Ejemplares similares